Precision BioSciences (NASDAQ:DTIL) CEO Sells $22,124.41 in Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) CEO Michael Amoroso sold 3,409 shares of the company’s stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $6.49, for a total value of $22,124.41. Following the completion of the transaction, the chief executive officer owned 115,575 shares in the company, valued at approximately $750,081.75. The trade was a 2.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Precision BioSciences Stock Performance

Shares of NASDAQ:DTIL traded down $0.67 during trading on Tuesday, hitting $6.69. 106,939 shares of the company were exchanged, compared to its average volume of 277,117. The company has a market cap of $78.88 million, a PE ratio of -0.76 and a beta of 1.79. The stock has a 50 day moving average of $5.75 and a 200 day moving average of $5.17. Precision BioSciences, Inc. has a 52-week low of $3.61 and a 52-week high of $8.82. The company has a debt-to-equity ratio of 0.66, a current ratio of 5.18 and a quick ratio of 5.18.

Precision BioSciences (NASDAQ:DTIL) last released its quarterly earnings results on Monday, November 3rd. The company reported ($1.84) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($1.53). Precision BioSciences had a negative return on equity of 176.47% and a negative net margin of 6,205.79%.The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $5.40 million. During the same period in the previous year, the company posted ($2.25) EPS. As a group, equities research analysts predict that Precision BioSciences, Inc. will post -1.23 EPS for the current year.

Hedge Funds Weigh In On Precision BioSciences

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Miller Financial Services LLC bought a new stake in shares of Precision BioSciences during the first quarter valued at approximately $48,000. Tejara Capital Ltd boosted its stake in shares of Precision BioSciences by 185.2% during the 1st quarter. Tejara Capital Ltd now owns 60,427 shares of the company’s stock worth $288,000 after acquiring an additional 39,242 shares during the last quarter. Corient Private Wealth LLC purchased a new position in shares of Precision BioSciences during the 2nd quarter valued at $425,000. Geode Capital Management LLC lifted its stake in shares of Precision BioSciences by 5.5% during the 2nd quarter. Geode Capital Management LLC now owns 77,712 shares of the company’s stock valued at $326,000 after buying an additional 4,025 shares in the last quarter. Finally, Bridgeway Capital Management LLC purchased a new position in shares of Precision BioSciences during the 2nd quarter valued at $260,000. Institutional investors own 37.99% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Precision BioSciences in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $47.00.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.